Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients…
Novartis, a leader reimagining rheumatology and immuno-dermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in…
Read More...
Read More...
